New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
07:25 EDTRNA, RNA, RNAProsensa to host special shareholder meeting
Special shareholder meeting to appoint Dr. Georges Gemayel as new supervisory board member will be held on January 23 at 8 am.
News For RNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
09:23 EDTRNAOn The Fly: Pre-market Movers
Subscribe for More Information
09:20 EDTRNAProsensa buyout not good for Sarepta, says Piper Jaffray
Piper Jaffray says it views the Prosensa (RNA) acquisition by BioMarin (BMRN) as bad for Sarepta (SRPT) since the company now has to compete with a "significantly more experienced and better funded orphan drug player." Piper adds that the takeover announced this morning has no impact on Sarepta's current drug filing process for its Duchenne muscular dystrophy drug eteplirsen. It keeps a Neutral rating on Sarepta with a $20 price target. The stock is trading up 9% in pre-market trading to $17.16 after BioMarin paid a healthy premium to acquire its peer Prosensa.
09:20 EDTRNABioMarin says Prosensa deal does not reflect deterioration of pipeline
Subscribe for More Information
08:12 EDTRNASarepta rises after DMD competitor acquired at significant premium
Shares of Sarepta Therapeutics (SRPT) are up 9.5% to $17.23 in early pre-market trading after rival drugmaker Prosensa (RNA) agreed to be acquired by BioMarin (BMRN). BioMarin has offered to purchase all of the outstanding ordinary shares of Prosensa for $17.75 per share, for a total up front consideration of approximately $680M. In addition, two approximately $80M contingent milestones are payable for the approval of drisapersen in the U.S. and Europe. Drisapersen is Prosensa's lead exon-skipping drug candidate for treating Duchenne muscular dystrophy, or DMD. Sarepta is at work on eteplirsen, its own exon-skipping therapeutic candidate for the treatment of DMD. Prosensa closed trading Friday at $11.44 and are up about 65% to $18.90 in pre-market trading following the deal announcement.
06:44 EDTRNABioMarin to host conference call
Subscribe for More Information
06:02 EDTRNABioMarin agrees to purchase all shares of Prosensa for $17.75 per share
Subscribe for More Information
November 17, 2014
07:04 EDTRNAProsensa reports Q3 EPS (EUR 0.29) vs. (EUR 0.12) last year
November 14, 2014
16:19 EDTRNAGIMV reports 1.43% passive stake in Prosensa
November 10, 2014
15:53 EDTRNACredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use